Skip to content

    Vidhi Specialty

    VIDHIING
    Chemicals·14 May 2026
    Management Summary

    Vidhi Specialty Food Ingredients Limited delivered a resilient performance in FY26, marked by improved profitability and strong financial health despite global headwinds. EBITDA margins expanded to 20.52% and net profit grew by 10.80%. The company is strategically investing in new product lines like CoatIcon and other value-added offerings, with significant capex planned for FY27 to drive future growth and diversify its portfolio.

    Highlights

    5
    • EBITDA margins improved from 17.91% to 20.52% in FY26, supported by better realizations and product mix.

    • Net profit grew by 10.80% to INR 49.15 crores in FY26, demonstrating profitability protection in a challenging environment.

    • Return on capital employed improved to 20.90% from 20.17% in FY26, reflecting efficient capital utilization.

    • CoatIcon tablet coating systems are in aggressive sampling and customer qualification stages with encouraging feedback.

    • Robust R&D and innovation pipeline with multiple exciting product ranges under development for future growth.

    Concerns

    3
    • Revenue slightly decreased to INR 380 crores in FY26 from INR 382.30 crores in FY25 amidst global economic uncertainty.

    • Interest coverage ratio reduced from 28.27% to 16.75% due to the withdrawal of subvention scheme on export finance.

    • Continued global economic uncertainty, geopolitical tensions, and demand slowdown in several international markets.

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹380 Cr-0.6%YoY
    2. 02EBITDA₹78 Cr+14.7%YoY
    3. 03EBITDA Margin20.5%
    4. 04Net Profit₹49.15 Cr+10.8%YoY
    5. 05Return on Capital Employed20.9%

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹75 crores

    Debt

    Debt disclosed

    Liquidity

    Liquidity disclosed

    Company continues to remain financially robust, with strong liquidity position.

    Guidance & targets

    8
    CategoryTargetPriority
    Profitability
    EBITDA Margin (Manufacturing Sales)
    24-25%
    High
    Profitability
    EBITDA Margin (Overall)
    rise even further
    Medium
    Capacity
    Utilization
    Full
    High
    Capex
    CoatIcon Capex
    INR 5-12 crores
    High
    Capex
    New Products Capex
    INR 75-85 crores
    High
    Operations
    New Products Commissioning
    middle of financial year '27-'28
    High
    Product Mix
    High-value product contribution
    10-12% or higher
    Medium
    Sales
    Dahej Project Sales
    INR 125-150 crores
    Medium

    CoatIcon product line progress

    next 18 months
    Currentaggressive sampling and customer qualification stages
    Targetcustomer approvals and commercialization

    Why it matters

    Key new product for the pharma sector with high margin potential, crucial for future growth and diversification.

    The product range is currently is in aggressive sampling and customer qualification stages, with several multi-pharmaceutical companies, both in India and international markets.

    How to verify

    guidance_and_targets[metric='New Products Commissioning']

    Risks & concerns

    4
    RiskSeverity

    Global economic uncertainty and geopolitical tensions

    The year gone by has been marked by significant global economic uncertainty, geopolitical tensions, tariff pressures and a noticeable slowdown in demand across several international markets.Management acknowledged

    medium

    Withdrawal of export finance subvention scheme

    The finance cost of the company has increased slightly due to the withdrawal of subvention scheme on export finance, which has been withdrawn by the Indian government as of December 2025.Management acknowledged

    low

    Volatility in US market due to tariff issues

    A lot of disturbances have been occurring because on account of this whole tariff tantrum that has been taking place over the whole last good period of last 12 months, which has brought in a lot of instability.Management acknowledged

    medium

    Economic slowdown in key export geographies (Middle East, Bangladesh, Philippines)

    As far as even the current scenario is concerned of this Middle Eastern conflict, what it has done is that a lot of the economies like, for example, even Iran itself is a big market for colors, which is completely out at this point of time.Management acknowledged

    medium

    Q&A highlights

    8

    “As far as '26, '27 is concerned, then we expect full utilization of both our Dahej and Roha facilities in this financial year. ... So if you see the actual EBITDA margin on manufactured sales, it would be close to 24%, 25%, which was what the target of the company was as far as synthetic food colors and certain other value-added products, which we are now increasing the sales from time to time.”

    Analyst sought clarity on future growth and profitability, which are core investment metrics, and management provided specific targets for capacity utilization and manufacturing EBITDA margins.

    asked by Gokul Maheshwari

    3 min read7 chapters

    Detailed Narrative

    01

    FY26 Performance and Profitability

    Despite global economic headwinds, Vidhi Specialty Food Ingredients Limited delivered a resilient performance in FY26. Revenue stood at INR 380 crores, a slight decrease from INR 382.30 crores in FY25. However, EBITDA improved to INR 78 crores from INR 68 crores, with margins expanding to 20.52% from 17.91%. Net profit grew by 10.80% to INR 49.15 crores, demonstrating strong profitability management even in a challenging environment.

    02

    Strategic Transformation and Product Development

    The company is accelerating its strategic transformation, focusing on higher value-added and application-driven segments. Significant progress has been made on the CoatIcon range of tablet coating systems, which are in aggressive sampling and customer qualification stages with several multi-pharmaceutical companies. The R&D pipeline remains robust, with multiple new product ranges under development, aligning with the vision of a diversified specialty ingredients platform catering to food, pharmaceutical, cosmetics, and allied industries.

    03

    Capex Plans and Timelines for New Projects

    Vidhi plans to invest INR 5-12 crores for the CoatIcon pharma product line scale-up and INR 75-85 crores in the first phase for other new products. Most of this capex is expected to be spent in FY27. Commissioning for these new product lines is anticipated in the middle of financial year '27-'28. Additionally, the company has invested INR 4.5-5 crores in analytical equipment for its R&D facilities, which house over 60 dedicated chemists.

    04

    Margin Expansion and Product Mix Optimization

    The EBITDA margin on manufactured sales was close to 24-25% in FY26, and overall EBITDA margins are expected to rise further as value-added and specialized products increase in quantity. The contribution of high-margin, high-value products in the total portfolio is currently around 5% and is expected to double to 10-12% (or higher) in FY27. This shift is a key strategy for sustainable growth and improved profitability, with new product lines expected to have excellent margin profiles due to thin competition.

    05

    US Market Dynamics and Export Performance

    The US market, a significant export destination, experienced volatility due to tariff issues, but the company managed to sustain sales. Management clarified that the export share to the US is 19% (for North America, not 44%) and that there is no US plan to ban synthetic food colors. While other markets like the Middle East, Bangladesh, and Philippines are currently facing economic slowdowns, the company expects the US market to open up substantially as geopolitical situations stabilize, leading to sharper demand.

    06

    Financial Health and Ratios

    The company maintains a robust financial position with a low debt-to-equity ratio of 0.28%. Return on capital employed improved to 20.90% from 20.17%, and return on equity increased to 14.94% from 14.92%. The interest coverage ratio, however, reduced from 28.27% to 16.75% due to the withdrawal of the export finance subvention scheme by the Indian government in December 2025, which increased finance costs.

    07

    Capacity Utilization and Future Outlook

    Vidhi expects full utilization of both its Dahej and Roha facilities in FY27, indicating robust demand and operational efficiency. The company's long-term vision includes a product pipeline for the next decade, with new products being commercialized every 18-24 months. The Dahej project, once commissioned, is expected to generate INR 125-150 crores in sales, contributing significantly to future revenue growth.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.